Research programme: HIV vaccines - Novartis

Drug Profile

Research programme: HIV vaccines - Novartis

Latest Information Update: 13 Jul 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 13 Jul 2010 Development discontinued for HIV infections during 2005
  • 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
  • 19 Feb 2004 Data presented at the 11th Conference on Retroviruses and Opportunistic Infections (CROI-2004) have been added to the Viral Infections immunogenicity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top